Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly, But the Right Test Will Hear It
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“Not every antigen speaks loudly…
But the right test will hear it.
In transfusion medicine, one of the most fascinating diagnostic tools we use to unmask hidden ABO subgroups is the Adsorption and Elution Test.
When routine serology says:
‘No antigen detected…’
This test asks again:
‘Are you absolutely sure?’
And sometimes — it finds what others miss.
Why Adsorption and Elution Matters
Some ABO subgroups (like weak A, weak B, A₃, Aₓ) express very low antigen levels on red cells.
These antigens:
- may not react in routine forward grouping
- may remain undetected even after incubation
- can create ABO discrepancies
- can affect transfusion safety if overlooked
That’s where Adsorption and Elution testing becomes powerful.
It helps us detect the hidden antigen behind the silence.
The Principle (Simple but Powerful)
- Red cells are incubated with anti-A or anti-B antibodies
- Weak antigens adsorb (bind) those antibodies
- Bound antibodies are eluted (released) from the cells
- The eluate is tested with A or B pooled cells
- Agglutination confirms the presence of the weak antigen
This confirms what routine testing could not reveal.
When Should You Think About Using It?
Consider Adsorption and Elution testing when:
- Forward and reverse grouping don’t match
- Weak A or weak B subgroup suspected
- Investigating ABO discrepancies
- Testing neonates or immunocompromised patients
- Resolving uncertain pre-transfusion typing
Why This Test Is So Important
Because accurate ABO subgroup identification means:
- safer transfusion decisions
- fewer compatibility surprises
- stronger laboratory confidence
- better patient outcomes
In transfusion medicine, precision saves lives.
Not every antigen shouts.
But with the right technique, we can still hear its voice.
Do you routinely perform Adsorption and Elution testing in your blood bank when resolving subgroup discrepancies?
Let’s learn from each other — Blood Doki”
Other posts featuring Augustina Isioma Ikusemoro on Hemostasis Today.
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA
-
May 5, 2026, 15:28Soumen Bhattacharyya: Hyperhomocysteinemia and Thrombosis – What Clinicians Should Know
-
May 5, 2026, 15:06Wolfgang Miesbach: How Should We Approach GI Angiodysplasia in VWD?
-
May 5, 2026, 14:48What Constitutes High Risk for Venous Thromboembolism? – JTH
-
May 5, 2026, 14:41How Real-Time Data, Rehabilitation Registries, and Patient-Reported Outcomes Can Transform Practice – European Stroke Organisation
-
May 5, 2026, 14:41Driving National Change for Bleeding Disorders – WFH